These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 32203383)

  • 1. Anti-CRISPR protein applications: natural brakes for CRISPR-Cas technologies.
    Marino ND; Pinilla-Redondo R; Csörgő B; Bondy-Denomy J
    Nat Methods; 2020 May; 17(5):471-479. PubMed ID: 32203383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CRISPR-Cas toolbox and gene editing technologies.
    Liu G; Lin Q; Jin S; Gao C
    Mol Cell; 2022 Jan; 82(2):333-347. PubMed ID: 34968414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research advances on the development and application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein system].
    Tan JJ; Peng YZ; Huang GT
    Zhonghua Shao Shang Za Zhi; 2021 Jul; 37(7):681-687. PubMed ID: 34304411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein Inhibitors of CRISPR-Cas9.
    Bondy-Denomy J
    ACS Chem Biol; 2018 Feb; 13(2):417-423. PubMed ID: 29251498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in CRISPR technologies for genome editing.
    Song M; Koo T
    Arch Pharm Res; 2021 Jun; 44(6):537-552. PubMed ID: 34164771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverse Mechanisms of CRISPR-Cas9 Inhibition by Type II Anti-CRISPR Proteins.
    Hwang S; Maxwell KL
    J Mol Biol; 2023 Apr; 435(7):168041. PubMed ID: 36893938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins.
    Lee J; Mir A; Edraki A; Garcia B; Amrani N; Lou HE; Gainetdinov I; Pawluk A; Ibraheim R; Gao XD; Liu P; Davidson AR; Maxwell KL; Sontheimer EJ
    mBio; 2018 Dec; 9(6):. PubMed ID: 30514786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Updates of CRISPR/Cas System and Anti-CRISPR Proteins: Innovative Applications to Improve the Genome Editing Strategies.
    Allemailem KS; Almatroudi A; Alrumaihi F; Alradhi AE; Theyab A; Algahtani M; Alhawas MO; Dobie G; Moawad AA; Rahmani AH; Khan AA
    Int J Nanomedicine; 2024; 19():10185-10212. PubMed ID: 39399829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR technologies for bacterial systems: Current achievements and future directions.
    Choi KR; Lee SY
    Biotechnol Adv; 2016 Nov; 34(7):1180-1209. PubMed ID: 27566508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergent CRISPR-Cas-based technologies for engineering non-model bacteria.
    Volke DC; Orsi E; Nikel PI
    Curr Opin Microbiol; 2023 Oct; 75():102353. PubMed ID: 37413959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas13 Inhibitors Block RNA Editing in Bacteria and Mammalian Cells.
    Lin P; Qin S; Pu Q; Wang Z; Wu Q; Gao P; Schettler J; Guo K; Li R; Li G; Huang C; Wei Y; Gao GF; Jiang J; Wu M
    Mol Cell; 2020 Jun; 78(5):850-861.e5. PubMed ID: 32348779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and applications of Type I CRISPR-Cas systems.
    Hidalgo-Cantabrana C; Barrangou R
    Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CRISPR-Cas Mechanism for Adaptive Immunity and Alternate Bacterial Functions Fuels Diverse Biotechnologies.
    Newsom S; Parameshwaran HP; Martin L; Rajan R
    Front Cell Infect Microbiol; 2020; 10():619763. PubMed ID: 33585286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA-Targeting CRISPR-Cas Systems and Their Applications.
    Burmistrz M; Krakowski K; Krawczyk-Balska A
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple mechanisms for CRISPR-Cas inhibition by anti-CRISPR proteins.
    Bondy-Denomy J; Garcia B; Strum S; Du M; Rollins MF; Hidalgo-Reyes Y; Wiedenheft B; Maxwell KL; Davidson AR
    Nature; 2015 Oct; 526(7571):136-9. PubMed ID: 26416740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
    Xu R; Wei P; Yang J
    Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas System: History and Prospects as a Genome Editing Tool in Microorganisms.
    Javed MR; Sadaf M; Ahmed T; Jamil A; Nawaz M; Abbas H; Ijaz A
    Curr Microbiol; 2018 Dec; 75(12):1675-1683. PubMed ID: 30078067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement.
    Li C; Brant E; Budak H; Zhang B
    J Zhejiang Univ Sci B; 2021 Apr; 22(4):253-284. PubMed ID: 33835761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas-based genome engineering in natural product discovery.
    Tong Y; Weber T; Lee SY
    Nat Prod Rep; 2019 Sep; 36(9):1262-1280. PubMed ID: 30548045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editing the microbiome the CRISPR way.
    Ramachandran G; Bikard D
    Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180103. PubMed ID: 30905295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.